Curis Lifesciences IPO Opens Today; ₹7.79 crore Raised from Anchor Investors.
By Shishta Dutta | Updated at: Nov 7, 2025 10:54 AM IST
Ahmedabad, November 7, 2025: Gujarat-based Curis Lifesciences Limited, a pharmaceutical manufacturer, opened its Initial Public Offering (IPO) for public subscription today. Ahead of the opening, the company raised ₹7.79 crore from six institutional investors through the anchor book on Thursday. The anchor portion witnessed notable participation from both domestic and international funds..
Curis Lifesciences Anchor Investor Allocation
According to the company board resolution dated November 6, 2025, 6,09,000 equity shares were decided to be allocated to the anchor investors at the cut-off price of ₹128 per equity share. This includes a premium of ₹118 per equity share. The anchor investors in the round were Sanshi Fund-I, Maiq Growth Scheme–Long Only, Strategic Sixth Sense Capital Fund, Viney Growth Fund, Zeta Global Funds (OEIC) PCC Limited – Zeta Series A Fund PC, and Moneywise Financial Services Pvt. Ltd. Among them, Sanshi Fund-I received the largest allocation, accounting for 25.78% of the anchor portion with an investment of ₹2.01 crore.
Curis Lifesciences IPO Structure and Key Dates
Curis Lifesciences IPO is a book build issue of ₹27.52 crores. The issue is entirely a fresh issue of 0.22 crore shares of ₹27.52 crore. Curis Lifesciences IPO bidding opened for subscription on Nov 7, 2025, and will close on Nov 11, 2025. The allotment for the Curis Lifesciences IPO is expected to be finalised on Nov 12, 2025. Curis Lifesciences IPO will list on NSE SME with a tentative listing date fixed as Nov 14, 2025.
Curis Lifesciences IPO price band is set at ₹120.00 to ₹128.00 per share. The lot size for an application is 1,000. The minimum amount of investment required by an individual investor (retail) is ₹2,56,000.00 (2,000 shares) (based on upper price). The minimum lot size investment for HNI is 3 lots (3,000 shares), amounting to ₹3,84,000.
Overview of the company
Curis Lifesciences was initially established in 2010 as M/s Loreto Pharmaceuticals. It is primarily engaged in the production of tablets, capsules, oral liquids, external preparations, and sterile ophthalmic ointments. The company operates a WHO-GMP-certified production unit at Sanand in Gujarat and supports more than 100 customers across 35 countries, like – Kenya, Yemen, Nigeria, Myanmar, and Vietnam.
The company reported a revenue of ₹49.13 crore and a net profit of ₹6.10 crore for the financial year 25. Most of the company’s sales have come from the Indian market. The company has over 900 approved formulations in its portfolio and is involved in loan license manufacturing, contract manufacturing, and direct exports.
Overview Strategic
The company plans to invest the IPO proceeds in expanding its capacity, increasing its export reach, and upgrading its R&D capabilities. The company’s growth commitment largely rests on two aspects: producing quality products and strict adherence to globally accepted standards.
Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.
If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.
Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations
